Forvia stock drops 7% over the week, analysts revise targets downward

A decline of 2.69% that extends a difficult week below moving averages

Forvia fell 2.69% to €8.82 mid-morning, after closing at €9.06 the previous day. The week is shaping up to be severe: the stock is down 7% over seven days, while the SBF 120 retreats 0.77% in the session. The decline is part of a longer-term dynamic, with the stock showing a decline of more than 24% over one year. Technically, the price is well below its three moving averages: the 20-day MA at €9.32 (gap of -5.36%), the 50-day MA at €9.15 (-3.61%) and the 200-day MA at €10.87 (-18.86%).

These three levels form a ceiling that has resisted each rebound attempt in recent weeks. The support at €8.60 remains the next zone to monitor, with the price only around twenty cents away this morning. The RSI at 46 remains in neutral territory, showing no signs of selling exhaustion.

Jefferies revises its target downward, CIC Market Solutions maintains its €14 target

The brief published yesterday on Jefferies' revision sheds partial light on the pressure being exerted this morning. The American bank lowered its price target from €14.05 to €11.35 while maintaining a positive view on the stock, signaling revised-down expectations on valuation, despite conviction about the equipment supplier's trajectory. At this stage, Jefferies' target of €11.35 still represents an upside potential of nearly 29% compared to the current price. This morning, CIC Market Solutions reiterates a buy rating with an unchanged target of €14.00, representing an indicated potential of nearly 59% — a gap that reflects the magnitude of valuation divergences on the stock.

To complete the picture, the analysts' consensus remains in marked variance with current trading levels. Furthermore, according to available disclosures, four funds cumulate 3.95% of capital in net short positions, a level nearly stable over thirty days (-0.01 point). This stock of short sales, elevated for a stock of this size, testifies to persistent distrust among a fraction of institutional investors, with no notable acceleration over the past month.